| Not Yet Recruiting | A Study of BEN301 Injection in the Treatment of Autoimmune Diseases SSC RA SS IIM | EARLY_Phase 1 | 2026-03-25 |
| Recruiting | A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases Relapsed/Refractory Autoimmune Diseases | EARLY_Phase 1 | 2026-03-09 |
| Recruiting | Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies | Phase 1 | 2025-11-06 |
| Recruiting | Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases Autoimmune Disease | N/A | 2025-02-20 |
| Recruiting | Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subje Light Chain Amyloidosis | N/A | 2025-02-20 |
| Recruiting | Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases Autoimmune Disease | N/A | 2025-02-20 |
| Not Yet Recruiting | A Study of CAR-T Cells Targeting Autoimmune Diseases Autoimmune Diseases | N/A | 2024-11-15 |
| Completed | Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Hematological Disorders, COVID-19 | N/A | 2023-01-12 |
| Withdrawn | Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphom T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | 2022-08-03 |
| Unknown | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 | 2022-05-25 |
| Completed | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 2 | 2022-03-24 |
| Withdrawn | Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 | 2022-02-16 |
| Terminated | A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumo Advanced Solid Tumor, Relapsed/Refractory Lymphoma | EARLY_Phase 1 | 2021-12-24 |
| Withdrawn | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 | 2021-12-13 |
| Completed | Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence | Phase 2 | 2021-12-01 |
| Completed | Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma T Cell Lymphoma, T-cell Leukemia | Phase 1 | 2021-09-14 |
| Terminated | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia T-Cell Acute Lymphoblastic Leukemia | Phase 1 | 2021-09-14 |
| Terminated | LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor T Cell Lymphoma, T-cell Leukemia | Phase 1 | 2021-07-02 |
| Completed | Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia, Relapse Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2021-04-08 |
| Completed | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 2 | 2020-05-01 |
| Terminated | Study of Sequential CAR-T Cell Treating Leukemia Children Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia | Phase 2 | 2020-05-01 |